2,3-bis(3'-hydroxybenzyl)butyrolactone has been researched along with hydroxymatairesinol in 10 studies
| Studies (2,3-bis(3'-hydroxybenzyl)butyrolactone) | Trials (2,3-bis(3'-hydroxybenzyl)butyrolactone) | Recent Studies (post-2010) (2,3-bis(3'-hydroxybenzyl)butyrolactone) | Studies (hydroxymatairesinol) | Trials (hydroxymatairesinol) | Recent Studies (post-2010) (hydroxymatairesinol) |
|---|---|---|---|---|---|
| 319 | 32 | 124 | 34 | 0 | 13 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahotupa, M; Eckerman, C; Franke, AA; Kangas, L; Mäkelä, SI; Reunanen, M; Saarinen, NM; Salmi, SM; Santti, R; Wärri, A | 1 |
| Collan, YU; Eckerman, C; Huovinen, R; Mäkelä, SI; Needham, L; Saarinen, NM; Santti, R; Valentín-Blasini, L; Wärri, A | 1 |
| Eklund, P; Lehtilä, R; Lindholm, A; Mikkola, JP; Sjöholm, R; Smeds, A | 1 |
| Korte, H; Lina, B; Nyman, L; Unkila, M | 1 |
| Hurmerinta, TT; Mäkelä, SI; Penttinen, PE; Saarinen, NM; Smeds, AI | 1 |
| Miura, D; Miura, Y; Saarinen, NM; Santti, R; Yagasaki, K | 1 |
| Bombelli, R; Cosentino, M; Crema, F; Delle Canne, MG; Ferrari, M; Lecchini, S; Legnaro, M; Luini, A; Luzzani, M; Marino, F; Paracchini, S; Rasini, E | 1 |
| Debouche, C; During, A; Larondelle, Y; Raas, T | 1 |
| Brown, DJ; Hardy, M; Tan, MO; Udani, JK | 1 |
| Andreoli, R; Archetti, I; Biasiotto, G; Cadei, M; De Palma, G; Di Lorenzo, D; Luzzani, M; Monti, E; Mozzoni, P; Pacchetti, B; Predolini, F; Serana, F; Smeds, A; Zanella, I | 1 |
10 other study(ies) available for 2,3-bis(3'-hydroxybenzyl)butyrolactone and hydroxymatairesinol
| Article | Year |
|---|---|
Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies).
Topics: 4-Butyrolactone; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Female; Furans; Genitalia, Male; Lignans; Male; Mammary Neoplasms, Experimental; Phytotherapy; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Trees; Uterus | 2000 |
Uptake and metabolism of hydroxymatairesinol in relation to its anticarcinogenicity in DMBA-induced rat mammary carcinoma model.
Topics: 4-Butyrolactone; 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Anticarcinogenic Agents; Diet; Estrogens, Non-Steroidal; Female; Isoflavones; Lignans; Mammary Neoplasms, Experimental; Organ Size; Phytoestrogens; Plant Preparations; Rats; Rats, Sprague-Dawley; Uterus | 2001 |
Synthesis of (-)-matairesinol, (-)-enterolactone, and (-)-enterodiol from the natural lignan hydroxymatairesinol.
Topics: 4-Butyrolactone; Furans; Hydrogenation; Lignans; Picea; Stereoisomerism | 2003 |
A thirteen week dietary toxicity study with 7-hydroxymatairesinol potassium acetate (HMRlignan) in rats.
Topics: 4-Butyrolactone; Animals; Body Weight; Diet; Female; Lignans; Male; Motor Activity; No-Observed-Adverse-Effect Level; Organ Size; Potassium Acetate; Rats; Rats, Wistar | 2005 |
Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo.
Topics: 4-Butyrolactone; 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinogens; Female; Furans; Lignans; Male; Mammary Neoplasms, Experimental; Molecular Structure; Organ Size; Phytotherapy; Plants; Prostate; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Uterus | 2005 |
Hydroxymatairesinol and its mammalian metabolite enterolactone reduce the growth and metastasis of subcutaneous AH109A hepatomas in rats.
Topics: 4-Butyrolactone; Animals; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Lignans; Liver Neoplasms, Experimental; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Rats; Tumor Cells, Cultured | 2007 |
Estrogenic activity of 7-hydroxymatairesinol potassium acetate (HMR/lignan) from Norway spruce (Picea abies) knots and of its active metabolite enterolactone in MCF-7 cells.
Topics: 4-Butyrolactone; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Lignans; Phytoestrogens; Picea; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tamoxifen | 2007 |
Among plant lignans, pinoresinol has the strongest antiinflammatory properties in human intestinal Caco-2 cells.
Topics: 4-Butyrolactone; Anti-Inflammatory Agents; Butylene Glycols; Caco-2 Cells; Cell Differentiation; Chemokine CCL2; Chromatography, High Pressure Liquid; Cyclooxygenase 2; Furans; Glucosides; Humans; Interleukin-1beta; Interleukin-6; Interleukin-8; Intestines; Lignans; NF-kappa B; Plant Extracts; Signal Transduction | 2012 |
Pharmacokinetics and bioavailability of plant lignan 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: a single-blinded, parallel, dose-comparison study.
Topics: 4-Butyrolactone; Aged; Biological Availability; Dose-Response Relationship, Drug; Female; Hot Flashes; Humans; Lignans; Middle Aged; Norway; Postmenopause; Single-Blind Method; Treatment Outcome | 2013 |
7-Hydroxymatairesinol improves body weight, fat and sugar metabolism in C57BJ/6 mice on a high-fat diet.
Topics: 3T3-L1 Cells; 4-Butyrolactone; Adipogenesis; Adipose Tissue; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Dietary Supplements; Fatty Liver; Gene Expression; Insulin Resistance; Lignans; Lipid Metabolism; Lipids; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Obesity; Picea; Plant Extracts | 2018 |